Ernexa Therapeutics Inc. (ERNA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company focused on developing cell therapies for cancer and autoimmune diseases. The reporting period covers the three and nine months ended September 30, 2025. The Company is classified as a non-accelerated filer and a smaller reporting company. As of November 7, 2025, there were 7,848,889 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $487 | $0 | $581 |
| Net Loss | $(1,240) | $(26,604) | $(12,582) | $(38,780) |
| Operating Expenses | $1,993 | $2,806 | $7,225 | $13,462 |
| Cash and Equivalents (End of Period) | $3,047 | $4,264 | $3,047 | $4,264 |
| Accumulated Deficit | $(244,126) | $(225,769) | $(244,126) | $(225,769) |
| Net Cash Used in Operating Activities (9M) | $(5,869) | $(12,291) | $(5,869) | $(12,291) |
Material Changes vs. Prior Period
- Revenue: Revenue was $0 for the three and nine months ended September 30, 2025, compared to $487,000 and $581,000 in the prior year periods. The prior year revenue was driven by the acceleration of recognition related to a customer contract assigned to Factor Bioscience in September 2024.
- Net Loss: Net loss improved significantly to $1.24 million for Q3 2025 from $26.6 million in Q3 2024. The prior year loss was heavily impacted by a $22.4 million loss on the extinguishment of debt and a $1.0 million fair value adjustment to bridge notes derivative liability.
- Operating Expenses: Total operating expenses decreased to $1.99 million in Q3 2025 from $2.81 million in Q3 2024. General and Administrative (G&A) expenses dropped significantly due to the termination of a sublease in August 2024 and reduced professional fees.
- Other Income/Expense: The Company recognized a $0.73 million gain on the extinguishment of debt in Q3 2025 related to time-barred liabilities. Conversely, the nine months ended September 30, 2025, included a $5.85 million non-cash expense related to a forward sales contract.
- Liquidity: Cash balances increased to $3.05 million as of September 30, 2025, from $1.73 million at year-end 2024, following a private placement that raised approximately $7.2 million in gross proceeds during the nine-month period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt regarding the Company's ability to continue as a going concern. With approximately $3.0 million in cash, the Company does not expect to have sufficient resources to fund operations for the twelve months following the issuance of this report. Additional capital is required through equity offerings, debt, or partnerships.
- Unusual Items:
- Forward Sales Contract Expense: A $5.85 million non-cash charge was recognized in the nine months ended September 30, 2025, related to the fair value of a forward sales contract entered into in March 2025.
- Debt Extinguishment Gain: A $0.73 million gain was recognized in Q3 2025 after legal counsel determined certain accounts payable and accrued expenses were time-barred under state statutes of limitations.
- Outlook: The Company expects to complete Investigational New Drug (IND) enabling studies and submission for its lead candidate, ERNA-101, by 2026. It is actively seeking strategic partnerships and applying for research grants.
- Risks: Key risks include the inability to raise additional capital, the preclinical nature of product candidates, and ongoing litigation (e.g., Donoghue v. Cherington and Ernexa).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.05 million cash balance against current burn rates and the timeline for the next capital raise.
- Going Concern Status: Review the specific plans and likelihood of success for raising additional capital to avoid insolvency within the next 12 months.
- Forward Sales Contract: Confirm the settlement status of the 2025 SPA and ensure no remaining liabilities or future non-cash charges are anticipated.
- Related Party Transactions: Review the terms of the promissory notes issued to and repaid by Charles Cherington, a significant shareholder and former director.
- Revenue Model: Assess the sustainability of revenue streams given the assignment of the primary customer contract to Factor Bioscience and the lack of current revenue-generating contracts.